Amir Imran Faisal Hamdi, Johnson Stanslas*
Oncologie, Vol.24, No.2, pp. 185-194, 2022, DOI:10.32604/oncologie.2022.023629
- 29 June 2022
Abstract KRAS mutations are among the most common oncogenic abnormalities in cancer. Until recently, drug discovery pursuing KRAS did not produce therapeutic benefits for patients. Specific KRAS inhibitors, such as sotorasib and adagrasib, which bind covalently to codon 12 of substituted glycine to cysteine residue of the protein (G12C), have been approved by the FDA recently for the treatment of lung cancers. Binding of these drugs to the protein inhibits the activation of the GDP-bound inactive state to the GTP-bound active state. Phase 1/2 trials have shown potential anti-tumor activity, particularly in patients with previously treated More >
Login
Register
